Compare CHWY & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHWY | DVA |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.0B |
| IPO Year | 2019 | 2002 |
| Metric | CHWY | DVA |
|---|---|---|
| Price | $26.00 | $152.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 24 | 4 |
| Target Price | $43.52 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 7.2M | 584.0K |
| Earning Date | 06-10-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.52 | ★ 9.84 |
| Revenue | $12,601,500,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $10.70 | $3.85 |
| Revenue Next Year | $7.84 | $3.07 |
| P/E Ratio | $49.56 | ★ $15.80 |
| Revenue Growth | 6.24 | ★ 6.46 |
| 52 Week Low | $22.74 | $101.00 |
| 52 Week High | $48.62 | $159.42 |
| Indicator | CHWY | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 53.54 |
| Support Level | $24.75 | $144.98 |
| Resistance Level | $27.77 | $152.31 |
| Average True Range (ATR) | 1.15 | 3.40 |
| MACD | -0.02 | 0.23 |
| Stochastic Oscillator | 27.67 | 68.58 |
Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending time developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.